EhmetDx revealed on Friday the receipt of US Food and Drug Administration (FDA) 510(k) clearance for its 3D CBCT positioning software for patient treatment.
In December 2018, the 3D CBCT positioning system will be used to precisely guide the position of the proton beam in patient treatment at the McLaren Proton Therapy Centre.
With patient treatment imminent, the company's team will turn its efforts to focus on commercialisation of the Mammoknife: the world's first self-shielded, linac-based breast cancer radiotherapy device that will raise the standard of treatment for women globally, added its founder and CEO Michael Teicher.
Headquartered in Plymouth, Michigan, EhmetDx is commercialising the latest identifiable needs of the medical market. It is a consortium of health care focused engineers, scientists and executives from diverse backgrounds that have collaborated to bring a sense of integrity and execution to the device industry.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval